Additional European Equity Opening News - 18th September 2026

AstraZeneca (AZN LN) - Co.'s Efzimfotase alfa granted Priority Review in the US as treatment for patients with hypophosphatasia aged 2 years and older. (AstraZeneca)

Investec (INVP LN) - Trading Statement: Expects H1 2027 Adj. EPS between GBP 0.417-0.433/shr (prev. GBP 0.405/shr Y/Y), adj. operating PBT between GBP 479.2-496.2mln (prev. GBP 468.1mln Y/Y). (Investec)

Societe Generale (GLE FP) - SocGen CEO Slawomir Krupa is expected to unveil higher profitability targets, further cost cuts and selective growth investments on 21st September, Bloomberg reports. Cuts are expected mainly in French retail banking and Ayvens, while investment may focus on trading, advisory, US expansion, data centre financing and Boursobank. Analysts expect continued emphasis on efficiency and capital discipline. (Bloomberg)

TotalEnergies (TTE FP) - Co. enters into a partnership agreement with Global Infrastructure Partners relating to TotalEnergies' interests in some oil & gas infrastructure assets in Africa. In exchange for a USD 1.8bln capital contribution, TotalEnergies will pay GIP a throughput-based tariff over a period of up to 15 years. (TotalEnergies)

TUI (TUI1 GY) - Co. says Lundgren will take over as Chair of the Supervisory Board, effective February 2027. (TUI)

Wizz Air (WIZZ LN) - Co. CEO says the revenue environment is improving and that they are cutting capacity for the winter period. (Bloomberg TV)

This is the standard European pre-open composite rather than a single event, and items of this kind tend to trade on their own merits at the open rather than setting a unified index tone, with the heaviest single-name moves historically coming from strategy resets and guidance changes rather than incremental deal or regulatory notices. The SocGen item carries the most precedent weight: incoming or mid-tenure European bank CEOs unveiling higher profitability targets and retail cost cuts have, on previous occasions across the French and broader sector, been rewarded where the market judged the cost programme credible and capital return untouched, and faded where targets relied on revenue growth; the tell will be whether the plan leans on French retail cuts, where delivery risk sits, or on trading and advisory. The TotalEnergies infrastructure partnership follows a well-worn integrated major pattern of monetising midstream and infrastructure stakes against throughput tariffs, which the market has generally read as balance-sheet friendly capital recycling rather than a change in upstream outlook. The AstraZeneca priority review is a routine regulatory milestone that shortens the review clock but carries no approval signal. Investec's guided raise and the Wizz Air capacity commentary slot into the usual open sequence, where outsized early moves in thin pre-market liquidity have tended to retrace once cash volumes arrive.